01946nas a2200349   4500000000100000008004100001260001300042653002500055653002600080653003000106653001300136653001100149653001400160653002300174653001200197653001300209653002700222653003100249653001500280653003000295100001300325700001200338700001200350700001400362245016800376856005900544300001100603490000700614050001500621520094600636022001401582       1994                            d  c1994 Dec10aConfidence Intervals10aDisability Evaluation10aDrug Therapy, Combination10aEthiopia10aHumans10aIncidence10aLeprostatic Agents10aleprosy10aNeuritis10aNeurologic Examination10aPreventive Health Services10aSkin Tests10aWorld Health Organization1 aRijk A J1 aGabre S1 aByass P1 aBerhanu T00aField evaluation of WHO-MDT of fixed duration, at ALERT, Ethiopia: the AMFES project--II. Reaction and neuritis during and after MDT in PB and MB leprosy patients.  uhttp://leprev.ilsl.br/pdfs/1994/v65n4/pdf/v65n4a05.pdf  a320-320 v65  aDERIJK19943 a<p>For a cohort of 286 leprosy patients the incidence rates and clinical manifestations of leprosy reactions during treatment and surveillance are described. Currently, individual patients had been observed for up to 4 years. It is intended that surveillance within this project should continue for up to 5 years after treatment. Of 128 PB patients, observed for 267 person-years (mean 2.1) 27 had 35 episodes of reaction, corresponding to an overall incidence rate of 131 events per 1000 person-years-at-risk (pyar). Of 158 MB patients observed for 402 person years (mean 2.5), 64 had 114 reactions, with an overall incidence of 284 events per 1000 pyar. For both PB and MB patients, incidence rates during treatment and post-MDT surveillance were similar. For PB patients, pre-existing physical impairment at the start of MDT was a significant risk factor for the occurrence of subsequent events, but this was not found in MB patients.</p>  a0305-7518